NCT00035789
Completed
Phase 3
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
ConditionsChronic Hepatitis B
DrugsEntecavir
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Chronic Hepatitis B
- Sponsor
- Bristol-Myers Squibb
- Locations
- 1
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E AntigenChronic Hepatitis BNCT00035633Bristol-Myers Squibb
Completed
Phase 3
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to LamivudineChronic Hepatitis BNCT00036608Bristol-Myers Squibb
Completed
Phase 2
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected PatientsHepatitis BNCT00051038Bristol-Myers Squibb
Active, not recruiting
Phase 2
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistanceHIV-1-infectionNCT04150068Gilead Sciences72
Terminated
Phase 4
Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute ExacerbationChronic Hepatitis BNCT01627223Taichung Veterans General Hospital17